Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections

The comparative efficacy of ceftazidime-avibactam and meropenem-vaborbactam for treatment of carbapenem-resistant Enterobacteriaceae (CRE) infections remains unknown. This was a multicenter, retrospective cohort study of adults with CRE infections who received ceftazidime-avibactam or meropenem-vabo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Antimicrob Agents Chemother
Autores principales: Ackley, Renee, Roshdy, Danya, Meredith, Jacqueline, Minor, Sarah, Anderson, William E., Capraro, Gerald A., Polk, Christopher
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Microbiology 2020
Materias:
Clinical Therapeutics
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7179589/
https://ncbi.nlm.nih.gov/pubmed/32094128
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02313-19
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares